Apple's Secret Blood Sugar Study Signals Big Tech Push Into Diabetes Management

Apple conducted a secret study to test a blood-sugar app in 2024, exploring potential consumer health tools as the diabetes technology landscape undergoes significant transformation across both monitoring and therapeutic devices.

The study was designed to explore possible uses for blood-sugar data and identify what tools Apple could potentially create for consumers, according to Bloomberg. The move comes as the continuous glucose monitoring (CGM) market experiences rapid expansion beyond traditional prescription-only diabetes management.

Consumer CGM Market Opens Up

The timing aligns with major regulatory shifts in glucose monitoring accessibility. Dexcom announced that its over-the-counter CGM device Stelo will be available without a prescription in August 2024, after submitting the sensor to the FDA for review in January 2024. The Stelo glucose monitor targets people with type 2 diabetes who don't use insulin—a significantly larger addressable market than traditional prescription CGM users.

This prescription-free approach represents a fundamental shift from established CGM devices like the Dexcom G5 Mobile, which was designed to replace fingerstick blood glucose testing for diabetes treatment decisions, and Abbott's FreeStyle Libre family. The FreeStyle Libre 3 Continuous Glucose Monitoring System is indicated for diabetes management in persons age 4 and older with Libre 3 Sensor users, while the Libre 2 Flash Glucose Monitoring System serves users age 2 and older with certain sensor variants.

Integrated Device Innovation

Hardware integration is advancing rapidly across the diabetes technology stack. Swiss technology maker Pharmasens demonstrated the niia signature, a semi-reusable tubeless patch pump and glucose sensor combined in one compact device that can be worn for five days. Meanwhile, Medtronic won CE mark for its MiniMed 780G automated insulin delivery system with the Simplera Sync sensor in January 2024.

The FDA also approved the Eversence device following a clinical study of 71 individuals aged 18 and over with type 1 and type 2 diabetes, adding to the expanding roster of implantable and wearable glucose monitoring options.

Biomarker Landscape Evolution

The broader diagnostic landscape is incorporating new biomarkers beyond traditional glucose measurements. The glycemic biomarker 1,5-anhydroglucitol (1,5-AHG) has demonstrated diagnostic applications for diabetes and shows potential for evaluating long-term complication risk, including cardiovascular diseases and mortality in people with type 2 diabetes mellitus.

Leptin has emerged as another significant marker, showing positive correlation with diabetes duration, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, serum insulin levels, cholesterol, triglycerides, and LDL cholesterol. Research identifies leptin as both a marker of insulin resistance and a possible diagnostic marker for type 2 diabetes mellitus.

Current screening protocols for type 2 diabetes rely on fasting blood sugar, hemoglobin A1C, glucose tolerance testing, and random plasma sugar measurements. For type 1 diabetes, established serum biomarkers include combinations of glucose, glycated molecules, c-peptide, and autoantibodies.

Regulatory Framework Adaptation

The FDA issued guidance for Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use in September 2020, establishing frameworks that now accommodate both traditional medical-grade devices and emerging consumer-focused solutions.

Looking at the broader trajectory here, we have seen this pattern before when consumer electronics companies entered established medical device markets. The smartphone's transformation of personal health tracking through accelerometers, heart rate sensors, and now blood oxygen monitoring suggests a similar pathway for glucose monitoring—but with significantly higher regulatory hurdles and clinical stakes.

Apple's investigation into blood-sugar applications represents more than platform expansion; it signals recognition that continuous metabolic monitoring could become as fundamental to personal health management as heart rate tracking. The company's existing Health app ecosystem and extensive sensor integration experience position it to potentially bridge the gap between medical-grade CGM accuracy and consumer-friendly data interpretation.

The convergence of over-the-counter CGM availability, integrated pump-sensor devices, and big tech health ambitions creates conditions for substantial market transformation. Traditional diabetes device manufacturers now face competition not just from each other, but from platform companies with different cost structures, user acquisition models, and data monetization strategies.

For healthcare providers and diabetes educators, this evolution presents both opportunities and challenges. Broader CGM adoption could improve population health outcomes through better glucose awareness, but may also require new frameworks for interpreting and acting on continuous metabolic data from patients using consumer-grade rather than medical-grade devices.

The integration of advanced biomarkers like 1,5-AHG and leptin into routine screening protocols, combined with continuous glucose data streams, could enable more nuanced diabetes risk assessment and management approaches. However, the clinical validation and standardization required for such integration remains substantial.

As Apple and other technology giants explore glucose monitoring applications, the diabetes technology landscape appears poised for significant disruption. The question is not whether consumer electronics companies will enter this space, but how quickly they can navigate regulatory requirements while delivering clinically meaningful tools that complement rather than complicate existing care pathways.